Abstract:Background
Silicon photomultiplier-positron emission tomography (SiPM-PET) has better sensitivity, spatial resolution, and timing resolution than photomultiplier tube (PMT)-PET. The present study aimed to clarify the advantages of SiPM-PET in 18F-fluoro-2-deoxy-D-glucose ([18F]FDG) brain imaging in a head-to-head comparison with PMT-PET in phantom and clinical studies.
Methods
Contrast was calculated from images acquired from a Hoffman 3D brain pha… Show more
“…When automated assessment of [ 18 F]FDG-PET images is performed, several aspects should be taken into consideration: Semiquantitative/voxel-based approaches to [ 18 F]FDG-PET analysis should always be used in conjunction with visual reading (considering visual reading as the first step for images evaluation and mandatory for quality control). Freeware and commercial software are available allowing for semiquantification or voxel-based analysis based on different methods [ 18 , 145 – 148 ]. Available freeware software for voxel-based analyses often are non-CE licensed.…”
The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.
“…When automated assessment of [ 18 F]FDG-PET images is performed, several aspects should be taken into consideration: Semiquantitative/voxel-based approaches to [ 18 F]FDG-PET analysis should always be used in conjunction with visual reading (considering visual reading as the first step for images evaluation and mandatory for quality control). Freeware and commercial software are available allowing for semiquantification or voxel-based analysis based on different methods [ 18 , 145 – 148 ]. Available freeware software for voxel-based analyses often are non-CE licensed.…”
The present procedural guidelines summarize the current views of the EANM Neuro-Imaging Committee (NIC). The purpose of these guidelines is to assist nuclear medicine practitioners in making recommendations, performing, interpreting, and reporting results of [18F]FDG-PET imaging of the brain. The aim is to help achieve a high-quality standard of [18F]FDG brain imaging and to further increase the diagnostic impact of this technique in neurological, neurosurgical, and psychiatric practice. The present document replaces a former version of the guidelines that have been published in 2009. These new guidelines include an update in the light of advances in PET technology such as the introduction of digital PET and hybrid PET/MR systems, advances in individual PET semiquantitative analysis, and current broadening clinical indications (e.g., for encephalitis and brain lymphoma). Further insight has also become available about hyperglycemia effects in patients who undergo brain [18F]FDG-PET. Accordingly, the patient preparation procedure has been updated. Finally, most typical brain patterns of metabolic changes are summarized for neurodegenerative diseases. The present guidelines are specifically intended to present information related to the European practice. The information provided should be taken in the context of local conditions and regulations.
“…The Discovery MI system is expected to have superior spatial resolution and sensitivity, compared with the Discovery PET/CT 710 system; however, upon visual inspection, the difference between the PET images obtained by each system is very small. 26 In addition, considering the FWHM values (less than 5 mm), the Discovery PET/CT 710 seems to have sufficient capacity for imaging the trimodal pattern and its collapse in the midbrain, as shown in Figure 2 (ie, both images came from the Discovery PET/CT 710). Meanwhile, we designated the AD group as a hallmark of nonparkinsonian disorders and found no significant difference in the MUR values between the AD and HC groups (Fig.…”
Section: Discussionmentioning
confidence: 98%
“…One of the limitations of the present study is that we analyzed the PET data together, which came from the Discovery PET/CT 710 and the Discovery MI. The Discovery MI system is expected to have superior spatial resolution and sensitivity, compared with the Discovery PET/CT 710 system; however, upon visual inspection, the difference between the PET images obtained by each system is very small 26 . In addition, considering the FWHM values (less than 5 mm), the Discovery PET/CT 710 seems to have sufficient capacity for imaging the trimodal pattern and its collapse in the midbrain, as shown in Figure 2 (ie, both images came from the Discovery PET/CT 710).…”
Background
18F-THK5351 PET is used to image ongoing astrogliosis by estimating monoamine oxidase B levels. 18F-THK5351 preferentially accumulates around the substantia nigra (SN) and periaqueductal gray (PG) in the midbrain under healthy conditions and exhibits a “trimodal pattern.” In progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS), the midbrain 18F-THK5351 uptake can be increased by astrogliosis, collapsing the “trimodal pattern.” We aimed to elucidate cases in which the “trimodal pattern” collapses in PSP and CBS.
Patients and Methods
Participants in the PSP (n = 11), CBS (n = 17), Alzheimer disease (n = 11), and healthy control (n = 8) groups underwent 18F-THK5351 PET. Volumes of interest (VOIs) were placed on the SN, PG, and their midpoints. The midbrain uptake ratio (MUR) was calculated to assess the trimodal pattern as follows: MUR = (VOI value on the midpoint)/(VOI value on the SN and PG). Approximately, the trimodal pattern can be identified at MUR <1 but not at MUR >1.
Results
Compared with the healthy control group, MUR significantly increased in the PSP (P < 0.01) and CBS (P < 0.01) groups, but was unchanged in the Alzheimer disease group (P = 0.10). In the PSP group, all patients, including 2 with mild symptoms and a short disease duration, showed MUR >1. In the CBS group, MUR varied widely.
Conclusions
In PSP, the trimodal pattern can collapse even in the early phase when symptoms are mild. In CBS, the trimodal pattern may or may not collapse depending on the underlying pathology.
“…Finally, we wish to underline the usefulness of semi-quantitative analysis to assist visual reading, as it has been widely evidenced by international literature [ 15 , 37 ]. We used Cortex ID suite, a fully automated post-processing software for quantifying 18 F-FDG PET/CT and beta-amyloid brain scans that used three-dimensional stereotactic surface projections (3D-SSP) for statistical image analysis [ 45 , 46 ]. Future works may focus on the combination of semi-quantitative analysis with direct extraction of traditional and/or deep learning imaging features from the brain scans, as discussed in [ 47 , 48 , 49 ].…”
Purpose: We evaluate the ability of Artificial Intelligence with automatic classification methods applied to semi-quantitative data from brain 18F-FDG PET/CT to improve the differential diagnosis between Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI). Procedures: We retrospectively analyzed a total of 150 consecutive patients who underwent diagnostic evaluation for suspected AD (n = 67) or MCI (n = 83). All patients received brain 18F-FDG PET/CT according to the international guidelines, and images were analyzed both Qualitatively (QL) and Quantitatively (QN), the latter by a fully automated post-processing software that produced a z score metabolic map of 25 anatomically different cortical regions. A subset of n = 122 cases with a confirmed diagnosis of AD (n = 53) or MDI (n = 69) by 18–24-month clinical follow-up was finally included in the study. Univariate analysis and three automated classification models (classification tree –ClT-, ridge classifier –RC- and linear Support Vector Machine –lSVM-) were considered to estimate the ability of the z scores to discriminate between AD and MCI cases in. Results: The univariate analysis returned 14 areas where the z scores were significantly different between AD and MCI groups, and the classification accuracy ranged between 74.59% and 76.23%, with ClT and RC providing the best results. The best classification strategy consisted of one single split with a cut-off value of ≈ −2.0 on the z score from temporal lateral left area: cases below this threshold were classified as AD and those above the threshold as MCI. Conclusions: Our findings confirm the usefulness of brain 18F-FDG PET/CT QL and QN analyses in differentiating AD from MCI. Moreover, the combined use of automated classifications models can improve the diagnostic process since its use allows identification of a specific hypometabolic area involved in AD cases in respect to MCI. This data improves the traditional 18F-FDG PET/CT image interpretation and the diagnostic assessment of cognitive disorders.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.